TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06293898: Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Sponsor: SystImmune Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 280 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT06293898 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06293898 Rescue Dossier →